XEDAR Antibody

Catalog No: #24427

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	XEDAR Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Affinity chromatography purified via peptide column
Applications	ELISA WB IHC
Species Reactivity	Hu
Immunogen Type	Recombinant protein
Immunogen Description	Raised against recombinant human XEDAR.
Target Name	XEDAR
Other Names	X-linked ectodysplasin-A2 receptor, EDA-A2 receptor, TNFRSF27
Accession No.	AAQ89953
Concentration	1mg/ml
Formulation	Supplied in PBS containing 0.02% sodium azide.
Storage	Can be stored at -20°C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images



Western blot analysis of XEDAR in 293 cell lysate with XEDAR antibody at (A) 0.5, (B) 1 and (C) 2 ug/mL.



Immunohistochemistry of XEDAR in human skin tissue with XEDAR antibody at 10 ug/mL.

Background

X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-κB and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

Note: This product is for in vitro research use only and is not intended for use in humans or animals.